儿童急性中耳炎伴耳漏三种抗生素给药策略的多中心随机非劣效试验方案
REST 研究为在英国 175 家全科诊所开展的多中心、实用性、三臂、个体随机、非劣效、开放试验,计划招募 399 名 ≥12 月龄且 <16 岁急性中耳炎伴耳漏患儿,比较即刻环丙沙星滴耳液、延迟口服阿莫西林(青霉素过敏者用克拉霉素)与即刻口服阿莫西林(克拉霉素)的疗效与安全性,主要结局为所有显著症状缓解时间。
要点
- 比较即刻滴耳、延迟口服与即刻口服抗生素对儿童 AOMd 的非劣效性。
- 主要结局由家长用症状恢复问卷报告所有显著症状缓解时间。
- 计划从英国 175 家全科诊所招募 399 名 ≥12 月龄且 <16 岁患儿。
核心结论
- REST 试验旨在评估即刻滴耳用环丙沙星或延迟口服阿莫西林(克拉霉素)相对于即刻口服阿莫西林(克拉霉素)在儿童 AOMd 中的非劣效性。
研究设计与样本
- 多中心、实用性、三臂、个体随机、非劣效、开放试验,在英国 175 家全科诊所开展。
- 计划招募 399 名 ≥12 月龄且 <16 岁、以 AOMd 就诊的儿童。
- 三臂分别为即刻环丙沙星 0.3% 滴耳液、延迟口服阿莫西林(青霉素过敏者用克拉霉素)、即刻口服阿莫西林(克拉霉素)。
- 使用 TRANSFoRm 电子试验管理平台完成资格筛查、随机化与数据采集,并整合初级保健电子病历。
关键数值与推荐
- 主要结局为所有显著症状缓解时间,由家长通过症状恢复问卷(SRQ)报告。
- 次要结局包括成本效果、中度或更差症状持续时间及 AOMd 复发次数,在第 14 天和 3 个月采集。
临床怎么用
- 为 AOMd 患儿选择即刻滴耳抗生素或延迟口服抗生素提供非劣效性证据,以支持减少即刻口服抗生素使用。
局限性
- 本文为研究方案,尚无疗效与安全性结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute otitis media (AOM) is a common painful infection in children, with around 2.8 million cases presenting to primary care in England and Wales annually. Nearly all children who present to their general practitioner (GP) with AOM or AOM with discharge (AOMd) are treated with orally administered antibiotics. These can cause side effects; contribute to the growing problem of antimicrobial resistance, and more rarely, allergic reactions. Alternative treatments, such as an antibiotic eardrops, or 'delayed' orally administered antibiotics, could be at least as effective and safe as immediate orally administered antibiotics for children with AOMd. METHODS/DESIGN: REST is a pragmatic, three-arm, individually randomised, non-inferiority trial being conducted in 175 GP practices across the United Kingdom (UK). The study aims to recruit 399 children aged (≥ 12 months and < 16 years) presenting to their GP with AOMd. Children will be randomised to one of three arms: immediate ciprofloxacin 0.3% eardrops; delayed orally administered amoxicillin (clarithromycin if penicillin allergic) or immediate orally administered amoxicillin (clarithromycin). Recruitment, including eligibility screening, randomisation and data collection, are conducted using the innovative, TRANSFoRm electronic trial management platform. Integrated within the primary care electronic medical records it provides automatic eligibility checking, part-filling of e-CRFs, study workflow management and routine NHS follow-up data collection. The primary outcome is time to resolution of all significant symptoms and will be collected by the parent using a Symptom Recovery Questionnaire (SRQ). Secondary outcomes, including cost-effectiveness, duration of moderately bad or worse symptoms and repeat AOMd episodes, will be collected at day-14 and at 3 months. DISCUSSION: It is unclear whether prescribing orally administered antibiotics to children with AOMd results in a reduction in symptoms or a shorter duration of illness. The REST trial should allow us to compare the non-inferiority of: immediate topically administered ciprofloxacin ear drops, or delayed orally administered amoxicillin (clarithromycin) against immediate orally administered amoxicillin (clarithromycin). We aim to recruit 399 patients from 175 practices in the UK. Using the TRANSFoRm software to randomise participants to the trial will enable recruitment for a relatively uncommon condition. TRIAL REGISTRATION: Name of Registry: ISCRTN Registration Number: ISRCTN12873692. This contains all items required to comply with the World Health Organization Trial Registration Data Set Date of Registration: 24 April 2018 Name of Registry: EudraCT Registration Number: 2017-003635-10 Date of Registration: 6 September 2017.
引用
- Curtis K, Moore M, Cabral C, et al. A multi-centre, pragmatic, three-arm, individually randomised, non-inferiority, open trial to compare immediate orally administered, immediate topically administered or delayed orally administered antibiotics for acute otitis media with discharge in children: The Runny Ear Study (REST): study protocol. Trials. 2020. PMID: 32493407. doi:10.1186/s13063-020-04419-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。